Assignee
ARMAGEN INC
US·9 granted patents·14 pending applications·26 citations·filing 2014–2025
Top patents by PatentIndex Score
23 records- 0194US2026078178A1Methods and compositions for increasing iduronate 2-sulfatase activity in the cnsARMAGEN INC·Filed 2025·Application pending·0 cites
- 0291US12043661B2Methods and compositions for increasing iduronate 2-sulfatase activity in the CNSARMAGEN INC·Filed 2021·Granted Jul 23, 2024·1 cites·10 claims
- 0391US11155631B2Macromolecular compositions that cross the blood-brain barrier and methods of use thereofARMAGEN INC·Filed 2015·Granted Oct 26, 2021·4 cites·5 claims
- 0491US10538589B2Methods and compositions for increasing N-acetylglucosaminidase (NAGLU) activity in the CNS using a fusion antibody comprising an anti-human insulin receptor antibody and NAGLUARMAGEN INC·Filed 2016·Granted Jan 21, 2020·4 cites·10 claims
- 0591US2024327507A1Methods and compositions for increasing iduronate 2-sulfate activity in the cnsARMAGEN INC·Filed 2024·Application pending·0 cites
- 0688US11512145B2Methods and compositions for increasing alpha-L-iduronidase activity in the CNSARMAGEN INC·Filed 2019·Granted Nov 29, 2022·2 cites·11 claims
- 0787US2024409650A1Methods and compositions for increasing n-acetylglucosaminidase activity in the cnsARMAGEN INC·Filed 2024·Application pending·0 cites
- 0886US10144783B2Macromolecular compositions that cross the blood-brain barrier and methods of use thereofARMAGEN INC·Filed 2014·Granted Dec 4, 2018·5 cites·22 claims
- 0984US10011651B2Methods and compositions for increasing iduronate 2-sulfatase activity in the CNSARMAGEN INC·Filed 2014·Granted Jul 3, 2018·4 cites·32 claims
- 1083US11028156B2Methods and compositions for increasing iduronate 2-sulfatase activity in the CNSARMAGEN INC·Filed 2018·Granted Jun 8, 2021·1 cites·14 claims
- 1182US10202467B2Methods and compositions for increasing α-L-iduronidase activity in the CNSARMAGEN INC·Filed 2017·Granted Feb 12, 2019·2 cites·4 claims
- 1282US2023279156A1Methods and compositions for increasing alpha-l-iduronidase activity in the cnsARMAGEN INC·Filed 2022·Application pending·0 cites
- 1381US9975955B2Methods and compositions for increasing arylsulfatase A activity in the CNSARMAGEN INC·Filed 2014·Granted May 22, 2018·3 cites·16 claims
- 1477US2022378932A1Fusion proteins for delivery of gdnf to the cnsARMAGEN INC·Filed 2022·Application pending·0 cites
- 1576US2022348672A1Methods and compositions for increasing enzyme activity in the cnsARMAGEN INC·Filed 2022·Application pending·0 cites
- 1676US2022127369A1Methods and compositions for increasing n-acetylglucosaminidase activity in the cnsARMAGEN INC·Filed 2022·Application pending·0 cites
- 1769US2020254113A1Fusion proteins for delivery of gdnf to the cnsARMAGEN INC·Filed 2020·Application pending·0 cites
- 1868US2021002379A1Methods and compositions for increasing n-acetylglucosaminidase activity in the cnsARMAGEN INC·Filed 2020·Application pending·0 cites
- 1966US2020308292A1Methods and compositions for increasing enzyme activity in the cnsARMAGEN INC·Filed 2020·Application pending·0 cites
- 2063US2025179201A1Methods and compositions for increasing galactosidase beta-1 activity in the cnsARMAGEN INC·Filed 2025·Application pending·0 cites
- 2159US2021403584A1Methods and compositions for increasing galactosidase beta-1 activity in the cnsARMAGEN INC·Filed 2020·Application pending·0 cites
- 2251US2024252667A1Methods and compositions for increasing the activity in the cns of hexosaminidase a, acid sphingomyelinase, and palmitoyl-protein thioesterase 1ARMAGEN INC·Filed 2019·Application pending·0 cites
- 2345US2022002688A1Purification of iduronate-2-sulfatase immunoglobulin fusion proteinARMAGEN INC·Filed 2019·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when ARMAGEN INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →